Ko Da Pharmaceutical Co. Ltd, Pingzhen Dist, No.20-1, Gongye 3rd Rd, Taoyuan, Taiwan.
Department of Nutrition, Master Program of Biomedical Nutrition, Hungkuang University, No. 1018 Sec. 6 Taiwan Boulevard, Taichung, 43302, Taiwan.
Probiotics Antimicrob Proteins. 2023 Oct;15(5):1102-1112. doi: 10.1007/s12602-022-09956-y. Epub 2022 Jul 7.
This study aimed to investigate the hepatoprotective effects of lyophilized powder of goji ferment (LPGF) against acetaminophen (APAP)-induced hepatic damage in Hep3B cells and in mice. Eleven strains of lactic acid bacteria (LAB) were selected and their hepatoprotection against APAP-induced cellular damage in Hep3B cell line was evaluated. Four strains of LAB, including BCRC11652 (Leuconostoc mesenteroides subsp. mesenteroides), BCRC14619 (Lactobacillus gasseri), KODA-1 (Pediococcus acidilactici), and KODA-2 (Limosilactobacillus fermentum), have hepatoprotective potential against APAP in vitro. Goji significantly stimulated the growth of individual and combined strains of LAB and the optimal fermented condition was the treatment of goji at 10% (w/w) for 24 h. The prepared lyophilized powder of goji ferment (LPGF) containing fifteen combinations of LAB strains was used to explore their hepatoprotection in vitro. LPGF containing all combinations of LAB strains, except for KODA-2, significantly restored APAP-reduced cell viability and improved APAP-increased cellular levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). In mice model, LPGF containing BCRC11652, BCRC14619, and KODA-2 was chosen to evaluate its hepatoprotection against APAP-induced liver injury. LPGF at diverse doses have a tendency but no significant improvement on APAP-reduced body weight gain and liver weight. LPGF significantly decreased APAP-increased serum ALT and AST levels in a dose-dependent manner. At the end of experiment, LPGF significantly and dose-dependently reversed APAP-reduced activities of GSH and antioxidant enzymes, including glutathione peroxidase, superoxide dismutase, and catalase in hepatic tissue. Overall, LPGF was demonstrated to exhibit hepatoprotection against APAP-induced liver injury in vitro and in vivo.
本研究旨在探讨枸杞发酵冻干粉（LPGF）对乙酰氨基酚（APAP）诱导的 Hep3B 细胞和小鼠肝损伤的保护作用。选择了 11 株乳酸菌（LAB），并评估了它们对 Hep3B 细胞系中 APAP 诱导的细胞损伤的保护作用。四种 LAB 菌株，包括 BCRC11652（肠膜明串珠菌亚种肠膜明串珠菌）、BCRC14619（格氏乳杆菌）、KODA-1（戊糖片球菌）和 KODA-2（发酵乳杆菌），具有体外抗 APAP 的潜在肝保护作用。枸杞显著刺激了单个和组合菌株 LAB 的生长，最佳发酵条件是 10%（w/w）枸杞处理 24 小时。制备的含有 15 种 LAB 菌株组合的冻干枸杞发酵粉（LPGF）用于体外探索其肝保护作用。含有除 KODA-2 之外的所有 LAB 菌株组合的 LPGF 显著恢复了 APAP 降低的细胞活力，并改善了 APAP 增加的细胞内丙氨酸氨基转移酶（ALT）和天冬氨酸氨基转移酶（AST）水平。在小鼠模型中，选择含有 BCRC11652、BCRC14619 和 KODA-2 的 LPGF 来评估其对 APAP 诱导的肝损伤的保护作用。不同剂量的 LPGF 对 APAP 降低的体重增加和肝重有一定的改善趋势，但无统计学意义。LPGF 显著降低了 APAP 增加的血清 ALT 和 AST 水平，呈剂量依赖性。实验结束时，LPGF 显著且剂量依赖性地逆转了 APAP 降低的肝组织 GSH 和抗氧化酶活性，包括谷胱甘肽过氧化物酶、超氧化物歧化酶和过氧化氢酶。总之，LPGF 被证明具有体外和体内抗 APAP 诱导的肝损伤的作用。
